RxDoctor Payments Data

Taiwo Kuye, MD

Internal Medicine · Harlingen, TXNPI 1891931820

Payments from drug & device makers

$3,938in general payments, 2019–2025

Across 232 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$970
  • Novo Nordisk$553
  • Insulet Corporation$324
  • GSK$270
  • AstraZeneca$195
  • Pfizer$143
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$3,84498%
  • Education$952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,938 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$58,872
Medicare patients
193
Services billed
847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide211$280,676
OzempicSemaglutide136$164,595
FarxigaDapagliflozin Propanediol72$66,281
RybelsusSemaglutide30$47,055
JardianceEmpagliflozin43$40,454
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt27$26,768
MyrbetriqMirabegron32$25,835
Tresiba Flextouch U-100Insulin Degludec28$21,746
LinzessLinaclotide18$18,004
TradjentaLinagliptin12$17,013
EliquisApixaban11$14,374
XareltoRivaroxaban17$14,343
Rosuvastatin Calcium273$3,396
Omega-3 Acid Ethyl Esters27$3,227
Atorvastatin Calcium198$1,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Insulin Lispro$970$282,138226 claims
Novo NordiskOzempic, Rybelsus$553$211,650166 claims
AstraZenecaFarxiga$195$66,28172 claims
Boehringer IngelheimJardiance, Tradjenta$43$57,46755 claims
Astellas Pharma US IncMyrbetriq$126$25,83532 claims
AbbVieLinzess$100$18,00418 claims
PfizerEliquis$143$14,37411 claims
Johnson & JohnsonXarelto$39$14,34317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Harlingen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →